The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Related News Articles

Headline
The Joint Commission and the Coalition for Health AI released guidance Sept. 17 on the responsible use of artificial intelligence in health care, the first…
Headline
The Healthcare Association of New York State Sept. 16 announced Bea Grause, R.N., its president and CEO, will retire in summer 2026. Grause was active for many…
Chairperson's File
Public
With all of the challenges facing health care — a shrinking workforce population, reduced funding, new technologies and pharmaceuticals — it's no longer an…
Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares how one of the nation’s largest health systems is putting artificial intelligence into…
Blog
Public
The Paragon Health Institute has published a series of new reports once again alleging large-scale “fraud” in health care. This time their target is enrollment…
Headline
The American Organization for Nursing Leadership Aug, 15 announced that Stuart Downs, DNP, R.N., was elected as the 2026 president-elect of the AONL Board of…